Physiol Rev Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Physiol. Rev. 77: 545-590, 1997;
0031-9333/97 $15.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stein, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stein, W. D.

Physiological Reviews, Vol 77, 545-590, Copyright © 1997 by American Physiological Society

JOURNAL ARTICLE

Kinetics of the multidrug transporter (P-glycoprotein) and its reversal

W. D. Stein
Department of Biological Chemistry, Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel.

Most cancer deaths result from the cancer's either being intrinsically resistant to chemotherapeutic drugs or becoming resistant after being initially sensitive. Often, in cells grown in cell culture, drug resistance correlates with the presence of one or more of the so-called P-glycoproteins or multidrug resistance proteins, products of the mdr family of genes. This review is largely concerned with the transport kinetics of the P-glycoproteins. We first present a brief overview of the P-glycoproteins, their properties, and their clinical significance. Later sections of the review expand on this material with special emphasis on the substrates of P-glycoprotein and how they cross the cell membrane, on the transport kinetics of the P-glycoprotein, on reversers of its action, and on its activity as an ATPase. In a final section, we consider the mechanism of action of P-glycoprotein as an actively transporting membrane pump. The characteristic of P-glycoprotein considered the most difficult to explain is its very broad specificity (or lack of specificity), but there are precedents for this property in well-known proteins such as serum albumin, which binds a range of molecular types, including substrates and reversers of P-glycoprotein, seemingly as broad as does P-glycoprotein. Pointing out this analogy does not provide a molecular explanation for the substrate-binding properties of P-glycoprotein but does make those properties more assimilable.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. J. De Blasio, M. Dodic, A. J. Jefferies, K. M. Moritz, E. M. Wintour, and J. A. Owens
Maternal exposure to dexamethasone or cortisol in early pregnancy differentially alters insulin secretion and glucose homeostasis in adult male sheep offspring
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E75 - E82.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi
Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System.
Physiol Rev, October 1, 2006; 86(4): 1179 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
T. T. Tran, A. Mittal, T. Aldinger, J. W. Polli, A. Ayrton, H. Ellens, and J. Bentz
The Elementary Mass Action Rate Constants of P-gp Transport for a Confluent Monolayer of MDCKII-hMDR1 Cells
Biophys. J., January 1, 2005; 88(1): 715 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Peer, Y. Dekel, D. Melikhov, and R. Margalit
Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models
Cancer Res., October 15, 2004; 64(20): 7562 - 7569.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Litman, T. Skovsgaard, and W. D. Stein
Pumping of Drugs by P-Glycoprotein: A Two-Step Process?
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 846 - 853.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. M. Johnson, W. N. Charman, and C. J. H. Porter
APPLICATION OF COMPARTMENTAL MODELING TO AN EXAMINATION OF IN VITRO INTESTINAL PERMEABILITY DATA: ASSESSING THE IMPACT OF TISSUE UPTAKE, P-GLYCOPROTEIN, AND CYP3A
Drug Metab. Dispos., September 1, 2003; 31(9): 1151 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. L. Urbatsch, G. A. Tyndall, G. Tombline, and A. E. Senior
P-glycoprotein Catalytic Mechanism: STUDIES OF THE ADP-VANADATE INHIBITED STATE
J. Biol. Chem., June 13, 2003; 278(25): 23171 - 23179.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Pavek, F. Staud, Z. Fendrich, H. Sklenarova, A. Libra, M. Novotna, M. Kopecky, M. Nobilis, and V. Semecky
Examination of the Functional Activity of P-glycoprotein in the Rat Placental Barrier Using Rhodamine 123
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1239 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Garrigues, N. Loiseau, M. Delaforge, J. Ferte, M. Garrigos, F. Andre, and S. Orlowski
Characterization of Two Pharmacophores on the Multidrug Transporter P-Glycoprotein
Mol. Pharmacol., December 1, 2002; 62(6): 1288 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-Y. Lee, I. L. Urbatsch, A. E. Senior, and S. Wilkens
Projection Structure of P-glycoprotein by Electron Microscopy. EVIDENCE FOR A CLOSED CONFORMATION OF THE NUCLEOTIDE BINDING DOMAINS
J. Biol. Chem., October 11, 2002; 277(42): 40125 - 40131.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Weiss and W. Kang
P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 688 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E.-j. Wang, K. Lew, C. N. Casciano, R. P. Clement, and W. W. Johnson
Interaction of Common Azole Antifungals with P Glycoprotein
Antimicrob. Agents Chemother., January 1, 2002; 46(1): 160 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Chen, A. C. Pant, and S. M. Simon
P-Glycoprotein Does Not Reduce Substrate Concentration from the Extracellular Leaflet of the Plasma Membrane in Living Cells
Cancer Res., November 1, 2001; 61(21): 7763 - 7769.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson
The Farnesyl Protein Transferase Inhibitor SCH66336 Is a Potent Inhibitor of MDR1 Product P-glycoprotein
Cancer Res., October 1, 2001; 61(20): 7525 - 7529.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson
Evaluation of the Interaction of Loratadine and desloratadine with P-glycoprotein
Drug Metab. Dispos., August 1, 2001; 29(8): 1080 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Sun, P. M. Bungay, and W. F. Elmquist
Effect of Capillary Efflux Transport Inhibition on the Determination of Probe Recovery During in Vivo Microdialysis in the Brain
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 991 - 1000.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Q. Mi, B. Cui, G. L. Silva, D. Lantvit, E. Lim, H. Chai, M. You, M. G. Hollingshead, J. G. Mayo, A. D. Kinghorn, et al.
Pervilleine A, a Novel Tropane Alkaloid that Reverses the Multidrug-resistance Phenotype
Cancer Res., May 1, 2001; 61(10): 4030 - 4037.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
O. Lomovskaya, M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, et al.
Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy
Antimicrob. Agents Chemother., January 1, 2001; 45(1): 105 - 116.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. G. C. T. van Oijen and P. J. Slootweg
Gain-of-Function Mutations in the Tumor Suppressor Gene p53
Clin. Cancer Res., June 1, 2000; 6(6): 2138 - 2145.
[Abstract] [Full Text]

Home page
 CirculationHome page
D. R. Abernethy and D. A. Flockhart
Molecular Basis of Cardiovascular Drug Metabolism : Implications for Predicting Clinically Important Drug Interactions
Circulation, April 11, 2000; 101(14): 1749 - 1753.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Krishan, K. S. Sridhar, C. Mou, W. D. Stein, E. Lyubimov, Y.-P. Hu, and H. Fernandez
Synergistic Effect of Prochlorperazine and Dipyridamole on the Cellular Retention and Cytotoxicity of Doxorubicin
Clin. Cancer Res., April 1, 2000; 6(4): 1508 - 1517.
[Abstract] [Full Text]

Home page
 JCBHome page
Y. Chen and S. M. Simon
In Situ Biochemical Demonstration that P-Glycoprotein Is a Drug Efflux Pump with Broad Specificity
J. Cell Biol., March 6, 2000; 148(5): 863 - 870.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
I. Peri, H. Mamrud-Brains, S. Rodin, V. Krizhanovsky, Y. Shai, S. Nir, and M. Naim
Rapid entry of bitter and sweet tastants into liposomes and taste cells: implications for signal transduction
Am J Physiol Cell Physiol, January 1, 2000; 278(1): C17 - C25.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Lerner-Marmarosh, K. Gimi, I. L. Urbatsch, P. Gros, and A. E. Senior
Large Scale Purification of Detergent-soluble P-glycoprotein from Pichia pastoris Cells and Characterization of Nucleotide Binding Properties of Wild-type, Walker A, and Walker B Mutant Proteins
J. Biol. Chem., December 3, 1999; 274(49): 34711 - 34718.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. N. Markham, E. Westhaus, K. Klyachko, M. E. Johnson, and A. A. Neyfakh
Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus
Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2404 - 2408.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
G. Ecker, M. Huber, D. Schmid, and P. Chiba
The Importance of a Nitrogen Atom in Modulators of Multidrug Resistance
Mol. Pharmacol., October 1, 1999; 56(4): 791 - 796.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. H. Dantzig, R. L. Shepard, K. L. Law, L. Tabas, S. Pratt, J. S. Gillespie, S. N. Binkley, M. T. Kuhfeld, J. J. Starling, and S. A. Wrighton
Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities
J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 854 - 862.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
G. D. Luker, K. R. Nilsson, D. F. Covey, and D. Piwnica-Worms
Multidrug Resistance (MDR1) P-glycoprotein Enhances Esterification of Plasma Membrane Cholesterol
J. Biol. Chem., March 12, 1999; 274(11): 6979 - 6991.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. R. Hammond, S. Lee, and P. J. Ferguson
[3H]Gemcitabine Uptake by Nucleoside Transporters in a Human Head and Neck Squamous Carcinoma Cell Line
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1185 - 1191.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Döppenschmitt, P. Langguth, C. G. Regårdh, T. B. Andersson, C. Hilgendorf, and H. Spahn-Langguth
Characterization of Binding Properties to Human P-Glycoprotein: Development of a [3H]Verapamil Radioligand-Binding Assay
J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 348 - 357.
[Abstract] [Full Text]

Home page
 BloodHome page
R. Robey, S. Bakke, W. Stein, B. Meadows, T. Litman, S. Patil, T. Smith, T. Fojo, and S. Bates
Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein-Mediated Drug Efflux by PSC 833
Blood, January 1, 1999; 93(1): 306 - 314.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. V. Ambudkar, C. O. Cardarelli, I. Pashinsky, and W. D. Stein
Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein
J. Biol. Chem., August 22, 1997; 272(34): 21160 - 21166.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. L. Urbatsch, K. Gimi, S. Wilke-Mounts, and A. E. Senior
Conserved Walker A Ser Residues in the Catalytic Sites of P-glycoprotein Are Critical for Catalysis and Involved Primarily at the Transition State Step
J. Biol. Chem., August 4, 2000; 275(32): 25031 - 25038.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. L. Urbatsch, K. Gimi, S. Wilke-Mounts, N. Lerner-Marmarosh, M.-E. Rousseau, P. Gros, and A. E. Senior
Cysteines 431 and 1074 Are Responsible for Inhibitory Disulfide Cross-linking between the Two Nucleotide-binding Sites in Human P-glycoprotein
J. Biol. Chem., July 13, 2001; 276(29): 26980 - 26987.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. D. Luker, T. P. Flagg, Q. Sha, K. E. Luker, C. M. Pica, C. G. Nichols, and D. Piwnica-Worms
MDR1 P-glycoprotein Reduces Influx of Substrates without Affecting Membrane Potential
J. Biol. Chem., December 21, 2001; 276(52): 49053 - 49060.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online